TY - JOUR
T1 - Transarterial Radioembolization Versus Systemic Treatment for Hepatocellular Carcinoma with Macrovascular Invasion
T2 - Analysis of the U.S. National Cancer Database
AU - Ahn, Joseph C.
AU - Lauzon, Marie
AU - Luu, Michael
AU - Friedman, Marc L.
AU - Kosari, Kambiz
AU - Nissen, Nicholas
AU - Lu, Shelly C.
AU - Roberts, Lewis R.
AU - Singal, Amit G.
AU - Yang, Ju Dong
N1 - Publisher Copyright:
© 2021 by the Society of Nuclear Medicine and Molecular Imaging.
PY - 2021/12/1
Y1 - 2021/12/1
N2 - Systemic therapy remains the recommended first-line treatment for hepatocellular carcinoma (HCC) with macrovascular invasion (MVI). Transarterial radioembolization (TARE) is a promising alternative treatment, given its potential to impart a superior quality of life. The aims of this study were, first, to characterize trends and correlates for TARE as a first-line treatment for HCC patients with MVI in the United States and, second, to compare survival after TARE versus systemic therapy. Methods: We used the U.S. National Cancer Database to identify patients with T3BN0M0 HCC during 2010-2017. We performed multivariable logistic regression to identify factors associated with use of TARE versus systemic therapy and Cox proportional-hazards regression to identify factors associated with overall survival. Results: Of 11,259 patients with T3BN0M0 HCC, 1,454 (12.9%) and 3,915 (34.7%) were treated with TARE and systemic therapy, respectively. The proportion of patients who received TARE increased from 13.0% in 2010 to 37.0% in 2017. Older age, white race, and receiving care at an academic cancer program were associated with receipt of TARE, whereas lack of insurance, higher model-for-end-stage-liver-disease score, Charlson comorbidity index of at least 3, and Northeast region were associated with receipt of systemic therapy. TARE was associated with reduced mortality compared with systemic therapy (adjusted hazard ratio, 0.74; 95% CI, 0.68-0.80), with consistent results observed in propensity-weighted analysis and across all examined subgroups. Conclusion: Use of TARE as first-line therapy for HCC with MVI has increased in the United States. Patient characteristics, region, and medical center type affected the use of TARE. TARE was associated with reduced mortality compared with systemic therapy for HCC patients with MVI.
AB - Systemic therapy remains the recommended first-line treatment for hepatocellular carcinoma (HCC) with macrovascular invasion (MVI). Transarterial radioembolization (TARE) is a promising alternative treatment, given its potential to impart a superior quality of life. The aims of this study were, first, to characterize trends and correlates for TARE as a first-line treatment for HCC patients with MVI in the United States and, second, to compare survival after TARE versus systemic therapy. Methods: We used the U.S. National Cancer Database to identify patients with T3BN0M0 HCC during 2010-2017. We performed multivariable logistic regression to identify factors associated with use of TARE versus systemic therapy and Cox proportional-hazards regression to identify factors associated with overall survival. Results: Of 11,259 patients with T3BN0M0 HCC, 1,454 (12.9%) and 3,915 (34.7%) were treated with TARE and systemic therapy, respectively. The proportion of patients who received TARE increased from 13.0% in 2010 to 37.0% in 2017. Older age, white race, and receiving care at an academic cancer program were associated with receipt of TARE, whereas lack of insurance, higher model-for-end-stage-liver-disease score, Charlson comorbidity index of at least 3, and Northeast region were associated with receipt of systemic therapy. TARE was associated with reduced mortality compared with systemic therapy (adjusted hazard ratio, 0.74; 95% CI, 0.68-0.80), with consistent results observed in propensity-weighted analysis and across all examined subgroups. Conclusion: Use of TARE as first-line therapy for HCC with MVI has increased in the United States. Patient characteristics, region, and medical center type affected the use of TARE. TARE was associated with reduced mortality compared with systemic therapy for HCC patients with MVI.
KW - hepatocellular carcinoma
KW - macrovascular invasion
KW - systemic treatment
KW - transarterial radioembolization
UR - http://www.scopus.com/inward/record.url?scp=85127987475&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85127987475&partnerID=8YFLogxK
U2 - 10.2967/JNUMED.121.261954
DO - 10.2967/JNUMED.121.261954
M3 - Article
C2 - 33837067
AN - SCOPUS:85127987475
SN - 0161-5505
VL - 62
SP - 1692
EP - 1701
JO - Journal of Nuclear Medicine
JF - Journal of Nuclear Medicine
IS - 12
ER -